What is GUIDED THERAPEUTCS INC's earnings per share (EPS)?

GUIDED THERAPEUTCS INC (GTHP) reported diluted earnings per share of -$0.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

GUIDED THERAPEUTCS INC (GTHP) Financials

GTHP

FY2025 annual

Revenue $767K +10857.1% YoY

Net Income -$3.2M -32.2% YoY

EPS (Diluted) -$0.04 YoY not available

Free Cash Flow -$1.1M +4.4% YoY

Market Cap $17.4M as of Oct 9, 2026

Price / Sales 22.7x on $767K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GTHP SEC filings page.

GUIDED THERAPEUTCS INC (GTHP) reported $767K in revenue for fiscal year 2025, up 10857.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GTHP FY2025 2026-10-03

Revenue is recovering and producing better gross profit, but operating overhead and liabilities still dominate how the business is financed.

Gross margin expanded from 28.6% in FY2024 to 74.5% in FY2025, but that improvement did not produce operating break-even because overhead still exceeded gross profit. Operating cash flow of -$1.1M was nearly identical to free cash flow of -$1.1M, showing the reported loss was accompanied by cash use rather than being driven mainly by non-cash charges.

The balance sheet is structurally strained: liabilities of $7.3M were more than five times assets of $1.3M. A current ratio of 0.1x indicates that current assets provide limited coverage for near-term liabilities.

Positive financing cash flow alongside negative operating cash flow indicates operations were not self-funded. Shares outstanding rose to 96.4M in FY2025 from 78.0M in FY2024, so external financing coincided with a larger share base while cash generation remained negative.

Financial Health Signals

Financial health score not available

GUIDED THERAPEUTCS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-175.45

GUIDED THERAPEUTCS INC scores -175.45, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($17.4M) relative to total liabilities ($7.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

GUIDED THERAPEUTCS INC passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

GUIDED THERAPEUTCS INC reported a net loss of $3.2M while operations used $1.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

GUIDED THERAPEUTCS INC reported an operating loss of $2.4M against $617K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

GUIDED THERAPEUTCS INC generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

EBITDA

-$476K

YoY+37.4%

QoQ-58.7%

GUIDED THERAPEUTCS INC's EBITDA was -$476K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 37.4% from the same quarter a year earlier. Against the prior quarter it is down 58.7%.

Net Income

-$605K

YoY+25.4%

QoQ-21.0%

GUIDED THERAPEUTCS INC reported -$605K in net income in Q2 2026. This represents an increase of 25.4% from the same quarter a year earlier. Against the prior quarter it is down 21.0%.

EPS (Diluted)

-$0.01

YoY0.0%

QoQ0.0%

GUIDED THERAPEUTCS INC earned -$0.01 per diluted share (EPS) in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Cash & Balance Sheet

Cash & Debt

$12K

YoY-93.5%

QoQ-96.7%

5Y CAGR-58.0%

10Y CAGR-5.9%

GUIDED THERAPEUTCS INC held $12K in cash against $53K in long-term debt as of Q2 2026, with $6.2M of liabilities due within a year.

Shares Outstanding

97M

YoY+20.2%

QoQ0.0%

5Y CAGR+48.7%

GUIDED THERAPEUTCS INC had 97M shares outstanding in Q2 2026. This represents an increase of 20.2% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$34K

YoY-74.4%

QoQ-24.4%

GUIDED THERAPEUTCS INC invested $34K in research and development in Q2 2026. This represents a decrease of 74.4% from the same quarter a year earlier. Against the prior quarter it is down 24.4%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

GTHP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GTHP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$767K+10857.1%	$7K-92.9%	$98K+653.8%	$13K-84.0%	$81K-20.6%	$102K+183.3%	$36K-36.8%	$57K-76.6%	$244K	$0-100.0%	$42K-35.4%	$65K-92.1%	$820K-75.4%	$3.3M-7.2%	$3.6M
Cost of Revenue	N/A	$196K+3820.0%	$5K-91.9%	$62K-23.5%	$81K+32.8%	$61K+248.8%	-$41K-158.6%	$70K-21.3%	$89K-83.2%	$530K+7.5%	$493K-8.2%	$537K-39.7%	$891K+45.8%	$611K+422.2%	$117K+210.4%	-$106K
Gross Profit	N/A	$571K+28450.0%	$2K-94.4%	$36K+152.9%	-$68K-440.0%	$20K	N/A	-$34K-6.3%	-$32K+88.8%	-$286K+42.0%	-$493K+0.4%	-$495K-272.2%	-$133K-163.6%	$209K-93.5%	$3.2M-13.0%	$3.7M
R&D Expenses	N/A	$469K-10.8%	$526K+130.7%	$228K+196.1%	$77K+11.6%	$69K-51.7%	$143K+17.2%	$122K-50.0%	$244K-26.9%	$334K-54.4%	$733K-50.4%	$1.5M-47.0%	$2.8M+1.7%	$2.7M-15.0%	$3.2M+16.1%	$2.8M
SG&A Expenses	N/A	$2.3M+77.7%	$1.3M-56.7%	$3.0M-0.3%	$3.0M+38.4%	$2.2M+137.9%	$913K+31.6%	$694K-35.6%	$1.1M	N/A	$2.8M-31.6%	$4.1M-11.8%	$4.6M+31.6%	$3.5M-9.9%	$3.9M+9.5%	$3.6M
Operating Income	N/A	-$2.4M-12.5%	-$2.1M+39.0%	-$3.5M-3.7%	-$3.3M-41.1%	-$2.4M-124.5%	-$1.1M-12.3%	-$937K	N/A	N/A	-$3.8M+38.7%	-$6.2M+28.2%	-$8.7M-31.2%	-$6.6M-54.3%	-$4.3M+36.6%	-$6.8M
EBITDA	N/A	-$2.4M-12.5%	-$2.1M+39.1%	-$3.4M-3.6%	-$3.3M-46.1%	-$2.3M-116.6%	-$1.1M-14.8%	-$916K	N/A	N/A	-$2.6M+49.8%	-$5.2M+30.4%	-$7.4M-20.9%	-$6.1M-56.8%	-$3.9M+41.7%	-$6.7M
Interest Expense	N/A	$617K+61.9%	$381K+37.1%	$278K-52.2%	$582K-49.4%	$1.1M+8.9%	$1.1M-25.2%	$1.4M	N/A	$1.1M-41.6%	$1.9M+43.9%	$1.3M+34.5%	$979K+2075.6%	$45K-37.5%	$72K-10.0%	$80K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.2M-32.2%	-$2.4M+30.7%	-$3.5M+19.6%	-$4.3M-109.7%	-$2.1M-641.9%	-$279K+85.5%	-$1.9M-289.1%	$1.0M	N/A	-$4.0M+42.5%	-$6.9M+30.2%	-$9.9M-37.0%	-$7.2M-65.7%	-$4.4M+34.5%	-$6.6M
EPS (Basic)	N/A	-$0.04+20.0%	-$0.05+28.6%	-$0.07+53.3%	-$0.15+16.7%	-$0.18-350.0%	-$0.04+93.1%	-$0.58-129.7%	$1.95-99.8%	$997.64	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.04	-$0.04	-$0.05+28.6%	-$0.07	-$0.15	-$0.18	-$0.04	-$0.58	$0.01	$0.00	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	78M	57M+12.1%	51M	33M	13M	10,767	3,302	65,227	0	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0-100.0%	$0	N/A	$60K	$117K	$0-100.0%	N/A	$0
Cost of Revenue	$0-100.0%	$0	N/A	$25K	$38K	$0-100.0%	N/A	$0-100.0%
Gross Profit	$0-100.0%	$0	N/A	$35K	$79K	$0-100.0%	N/A	$0+100.0%
R&D Expenses	$34K-74.4%	$45K-39.2%	N/A	$136K+22.5%	$133K-40.1%	$74K+37.0%	N/A	$111K+60.9%
SG&A Expenses	$423K-35.7%	$451K+68.9%	N/A	$362K-3.2%	$658K+80.8%	$267K+13.1%	N/A	$374K-22.2%
Operating Income	-$478K+37.4%	-$302K+27.1%	N/A	-$485K+13.5%	-$763K-16.5%	-$414K-15.3%	N/A	-$561K+10.0%
EBITDA	-$476K+37.4%	-$300K+27.2%	N/A	-$483K+13.6%	-$760K-16.6%	-$412K-15.4%	N/A	-$559K+10.0%
Interest Expense	$136K-13.4%	$151K+2.7%	N/A	$129K+19.4%	$157K+109.3%	$147K+129.7%	N/A	$108K+52.1%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$605K+25.4%	-$500K-17.1%	N/A	-$742K-13.5%	-$811K-14.4%	-$427K-106118.9%	N/A	-$654K+3.4%
EPS (Basic)	-$0.010.0%	-$0.010.0%	-$0.01+50.0%	-$0.010.0%	-$0.010.0%	-$0.010.0%	-$0.02	-$0.010.0%
EPS (Diluted)	-$0.010.0%	-$0.010.0%	-$0.01+50.0%	-$0.010.0%	-$0.010.0%	-$0.01	-$0.02	-$0.010.0%
Diluted Shares (Avg)	97M+22.4%	89M+30.1%	N/A	82M+43.2%	79M+40.8%	68M	N/A	57M+10.8%

GTHP Balance Sheet

GTHP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.3M-3.9%	$1.4M-17.4%	$1.7M-50.4%	$3.4M+65.0%	$2.0M+51.1%	$1.4M+14.4%	$1.2M+400.0%	$236K-41.9%	$406K-72.8%	$1.5M-40.7%	$2.5M-17.0%	$3.0M-8.6%	$3.3M-4.7%	$3.5M-19.3%	$4.3M
Current Assets	$605K-49.5%	$1.2M-14.1%	$1.4M-53.6%	$3.0M+83.5%	$1.6M+82.7%	$896K-13.0%	$1.0M+425.5%	$196K-34.0%	$297K-71.6%	$1.0M-50.8%	$2.1M+19.4%	$1.8M-12.8%	$2.0M+8.9%	$1.9M-35.2%	$2.9M
Cash & Equivalents	$63K-83.8%	$388K-34.3%	$591K-74.4%	$2.3M+259.7%	$643K+253.3%	$182K-79.8%	$899K	$0-100.0%	$1K-92.9%	$14K-60.0%	$35K-78.4%	$162K-73.6%	$613K-41.3%	$1.0M-52.5%	$2.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$448K-29.2%	$633K+0.2%	$632K+15.3%	$548K-4.0%	$571K-5.6%	$605K+1160.4%	$48K-57.9%	$114K-37.4%	$182K-76.5%	$773K-30.9%	$1.1M-5.2%	$1.2M-1.1%	$1.2M+127.7%	$524K+0.8%	$520K
Accounts Receivable	$4K+33.3%	$3K-57.1%	$7K+16.7%	$6K-87.0%	$46K+91.7%	$24K+84.6%	$13K0.0%	$13K+333.3%	$3K	$0-100.0%	$190K-43.8%	$338K+154.1%	$133K+24.3%	$107K-8.5%	$117K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.3M+17.0%	$6.3M+14.5%	$5.5M-12.4%	$6.2M-16.5%	$7.5M-38.7%	$12.2M-32.6%	$18.1M+12.8%	$16.1M-18.9%	$19.8M+84.1%	$10.8M+33.2%	$8.1M+7.8%	$7.5M+119.0%	$3.4M+46.0%	$2.3M-14.2%	$2.7M
Current Liabilities	$6.6M+7.8%	$6.2M+28.0%	$4.8M-1.2%	$4.9M-14.5%	$5.7M-36.5%	$9.0M-27.8%	$12.4M+12.9%	$11.0M-7.2%	$11.8M+26.9%	$9.3M+70.7%	$5.5M+18.9%	$4.6M+159.8%	$1.8M-24.4%	$2.3M-14.1%	$2.7M
Non-Current Liabilities	$694K+519.6%	$112K-83.2%	$666K-51.7%	$1.4M-22.9%	$1.8M-44.8%	$3.2M-43.2%	$5.7M+12.6%	$5.1M-36.3%	$8.0M+460.7%	$1.4M-45.5%	$2.6M-9.9%	$2.9M+75.2%	$1.7M	$0-100.0%	$4K
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$22K-4.3%	$23K	$0-100.0%	$5.1M-36.3%	$8.0M	N/A	N/A	$40K-61.2%	$103K	$0-100.0%	$4K
Total Equity	-$6.0M-22.8%	-$4.9M-28.5%	-$3.8M-32.0%	-$2.9M+47.1%	-$5.4M+49.8%	-$10.9M+35.9%	-$16.9M-7.0%	-$15.8M+18.4%	-$19.4M-109.4%	-$9.3M-66.6%	-$5.6M-24.6%	-$4.5M-4072.9%	-$107K-109.4%	$1.1M-28.2%	$1.6M
Retained Earnings	-$157.1M-2.2%	-$153.7M-1.7%	-$151.1M-2.6%	-$147.4M-3.5%	-$142.4M-1.7%	-$140.0M-0.3%	-$139.6M-1.4%	-$137.6M+0.6%	-$138.5M-8.6%	-$127.6M-4.1%	-$122.6M-8.4%	-$113.1M-9.7%	-$103.0M-11.9%	-$92.1M-8.2%	-$85.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.2M+27.1%	$1.6M+65.9%	$1.3M-3.9%	$903K-27.7%	$940K-24.9%	$967K-35.3%	$1.4M-17.4%	$1.2M-33.5%
Current Assets	$527K-35.0%	$911K+12.3%	$605K-49.5%	$799K-23.4%	$811K-20.6%	$811K-34.6%	$1.2M-14.1%	$1.0M-33.9%
Cash & Equivalents	$12K-93.5%	$369K+220.9%	$63K-83.8%	$87K-55.2%	$185K-32.7%	$115K-74.2%	$388K-34.3%	$194K-73.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$500K-16.0%	$469K-25.9%	$448K-29.2%	$583K-8.3%	$595K-5.9%	$633K+0.2%	$633K+0.2%	$636K-1.9%
Accounts Receivable	$4K-50.0%	$4K+100.0%	$4K+33.3%	$6K+200.0%	$8K+300.0%	$2K-71.4%	$3K-57.1%	$2K-71.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.0M+8.5%	$6.8M+13.1%	$7.3M+17.0%	$6.5M+6.2%	$6.4M+8.3%	$6.0M+8.9%	$6.3M+14.5%	$6.2M+11.6%
Current Liabilities	$6.2M-3.3%	$6.0M+1.1%	$6.6M+7.8%	$6.5M+7.4%	$6.4M+11.3%	$5.9M+10.4%	$6.2M+28.0%	$6.0M+24.6%
Non-Current Liabilities	$789K+2154.3%	$818K+752.1%	$694K+519.6%	$79K-44.4%	$35K-81.2%	$96K-41.5%	$112K-83.2%	$142K-79.5%
Long-Term Debt	$53K	$91K	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$5.8M-5.3%	-$5.2M-2.9%	-$6.0M-22.8%	-$5.6M-14.8%	-$5.5M-17.2%	-$5.0M-25.3%	-$4.9M-28.5%	-$4.9M-34.7%
Retained Earnings	-$158.7M-2.4%	-$158.1M-2.5%	-$157.1M-2.2%	-$155.8M-1.8%	-$155.0M-1.8%	-$154.2M-1.7%	-$153.7M-1.7%	-$153.0M-1.6%

Not reported in any period shown, so not listed: Goodwill.

GTHP Cash Flow Statement

GTHP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$1.5M	-$1.1M+4.6%	-$1.1M+35.9%	-$1.7M-18.1%	-$1.5M+7.1%	-$1.6M+15.1%	-$1.9M-132.6%	-$806K	N/A	-$1.1M+36.5%	-$1.8M	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	N/A	$10K+11.1%	$9K0.0%	$9K+125.0%	$4K-95.2%	$83K	$0-100.0%	$21K-22.2%	$27K-87.3%	$213K-82.6%	$1.2M+16.0%	$1.1M-15.0%	$1.2M+169.0%	$461K+27.7%	$361K+961.8%	$34K
Stock-Based Compensation	N/A	$377K+214.2%	$120K-93.4%	$1.8M+30.8%	$1.4M+505.7%	$228K-26.4%	$310K+3773.8%	$8K-81.8%	$44K-25.4%	$59K-37.9%	$95K-90.6%	$1.0M+13.8%	$886K+7.5%	$824K+27.8%	$645K-25.9%	$870K
Capital Expenditures	N/A	$2K	$0	$0-100.0%	$31K+121.4%	$14K+1300.0%	$1K	$0	N/A	N/A	$0-100.0%	$8K	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	-$1.1M+4.4%	-$1.1M+35.9%	-$1.7M-15.6%	-$1.5M+6.0%	-$1.6M+14.4%	-$1.9M-132.8%	-$806K	N/A	N/A	-$1.8M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$2K	$0	N/A	-$31K-121.4%	-$14K-1300.0%	-$1K	$0	N/A	N/A	$0+100.0%	-$8K+94.7%	-$150K-40.2%	-$107K+80.6%	-$552K+21.6%	-$704K
Financing Cash Flow	$1.3M	$745K-18.7%	$916K+3716.7%	$24K-99.2%	$3.2M+53.8%	$2.1M+78.3%	$1.2M-32.0%	$1.7M	N/A	$1.1M-36.5%	$1.8M-54.6%	$3.9M-34.4%	$6.0M+14.4%	$5.2M+70.8%	$3.1M+29.2%	$2.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$319K-88.8%	-$617K-86.4%	-$291K+12.3%	-$277K+41.4%	-$169K+21.0%	-$331K-231.0%	-$332K+1.2%	-$473K0.0%
Depreciation & Amortization	$2K-33.3%	$2K0.0%	$3K+50.0%	$2K0.0%	$3K0.0%	$2K0.0%	$2K0.0%	$2K0.0%
Stock-Based Compensation	N/A	$68K+257.9%	N/A	N/A	N/A	$19K+63233.3%	N/A	N/A
Capital Expenditures	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
Free Cash Flow	N/A	N/A	-$291K+12.3%	N/A	N/A	N/A	-$332K+1.2%	N/A
Investing Cash Flow	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
Financing Cash Flow	-$38K-115.9%	$923K+1491.4%	$267K-49.2%	$181K-53.8%	$239K+443.2%	$58K+226.1%	$526K+168.4%	$392K+354.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

GTHP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GTHP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	74.5%+45.9pp	28.6%-8.2pp	36.7%	-523.1%	24.7%	N/A	-94.4%-38.3pp	-56.1%	-117.2%	N/A	-1178.6%	-204.6%	25.5%-71.0pp	96.5%	102.9%
Operating Margin	-309.3%	-30114.3%	-3527.6%	-25638.5%	-2916.0%	-1031.4%	-2602.8%	N/A	N/A	N/A	-14826.2%	-13336.9%	-805.6%	-128.3%	-187.8%
Net Margin	-416.7%	-34528.6%	-3560.2%	-33392.3%	-2555.6%	-273.5%	-5336.1%	1782.5%	N/A	N/A	-16433.3%	-15204.6%	-879.9%	-130.4%	-184.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-384.2%+37.1pp	-421.3%
Return on Assets	-241.4%-66.0pp	-175.4%+33.7pp	-209.1%-80.1pp	-129.0%-27.5pp	-101.5%-80.8pp	-20.7%+142.1pp	-162.8%-593.3pp	430.5%	N/A	-266.1%+8.3pp	-274.4%+51.6pp	-326.1%-108.5pp	-217.6%-92.4pp	-125.2%+29.0pp	-154.2%
Current Ratio	0.09-0.1x	0.19-0.1x	0.29-0.3x	0.62+0.3x	0.29+0.2x	0.100.0x	0.08+0.1x	0.020.0x	0.03-0.1x	0.11-0.3x	0.390.0x	0.39-0.8x	1.15+0.4x	0.80-0.3x	1.06
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x	0.00
Asset Turnover	0.58+0.6x	0.01-0.1x	0.06+0.1x	0.000.0x	0.040.0x	0.080.0x	0.03-0.2x	0.24-0.4x	0.60+0.6x	0.000.0x	0.020.0x	0.02-0.2x	0.25-0.7x	0.96+0.1x	0.83
FCF Margin	-139.5%	-15985.7%	-1781.6%	-11615.4%	-1982.7%	-1839.2%	-2238.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	N/A	N/A	N/A	58.3%	67.5%	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-808.3%	-652.1%	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-1236.7%	-693.2%	N/A	N/A	N/A
Return on Assets	-50.6%+35.7pp	-31.2%+13.0pp	N/A	-82.2%-29.8pp	-86.3%-29.6pp	-44.2%-44.1pp	N/A	-52.4%-16.3pp
Current Ratio	0.090.0x	0.150.0x	0.09-0.1x	0.120.0x	0.13-0.1x	0.14-0.1x	0.19-0.1x	0.17-0.2x
Asset Turnover	0.00-0.1x	0.000.0x	N/A	0.07+0.1x	0.12+0.1x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$6.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
GUIDED THERAPEUTCS INC GTHP	FY2025	$767K	-$3.2M	N/A	$17.4M	—
CS DIAGNOSTICS CORP CSDX	FY2024	N/A	$761	N/A	$2.1M	—
PETVIVO HOLDINGS INC PETV	FY2026	$1.1M	-$10.5M	N/A	$28.3M	—
BIOTRICITY INC BTCY	FY2026	$16.0M	-$2.4M	-15.0%	$14.3M	—

Where GUIDED THERAPEUTCS INC Ranks

Frequently Asked Questions

What is GUIDED THERAPEUTCS INC's annual revenue?

GUIDED THERAPEUTCS INC (GTHP) reported $767K in total revenue for fiscal year 2025. This represents a 10857.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is GUIDED THERAPEUTCS INC's revenue growing?

GUIDED THERAPEUTCS INC (GTHP) revenue grew by 10857.1% year-over-year, from $7K to $767K in fiscal year 2025.

Is GUIDED THERAPEUTCS INC profitable?

No, GUIDED THERAPEUTCS INC (GTHP) reported a net income of -$3.2M in fiscal year 2025.

What is GUIDED THERAPEUTCS INC's EBITDA?

GUIDED THERAPEUTCS INC (GTHP) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is GUIDED THERAPEUTCS INC's gross margin?

GUIDED THERAPEUTCS INC (GTHP) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is GUIDED THERAPEUTCS INC's free cash flow?

GUIDED THERAPEUTCS INC (GTHP) recorded an outflow of $1.1M in free cash flow during fiscal year 2025. This represents a 4.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is GUIDED THERAPEUTCS INC's operating cash flow?

GUIDED THERAPEUTCS INC (GTHP) recorded an outflow of $1.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are GUIDED THERAPEUTCS INC's total assets?

GUIDED THERAPEUTCS INC (GTHP) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are GUIDED THERAPEUTCS INC's capital expenditures?

GUIDED THERAPEUTCS INC (GTHP) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does GUIDED THERAPEUTCS INC spend on research and development?

GUIDED THERAPEUTCS INC (GTHP) invested $469K in research and development during fiscal year 2025.

How many shares does GUIDED THERAPEUTCS INC have outstanding?

GUIDED THERAPEUTCS INC (GTHP) had 96M shares outstanding as of fiscal year 2025.

What is GUIDED THERAPEUTCS INC's current ratio?

GUIDED THERAPEUTCS INC (GTHP) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is GUIDED THERAPEUTCS INC's return on assets (ROA)?

GUIDED THERAPEUTCS INC (GTHP) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is GUIDED THERAPEUTCS INC's P/E ratio?

GUIDED THERAPEUTCS INC (GTHP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $17.4M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is GUIDED THERAPEUTCS INC's price-to-sales ratio?

GUIDED THERAPEUTCS INC (GTHP) trades at 22.7x sales, its market capitalization divided by revenue of $767K revenue, FY2025. The market capitalization is $17.4M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does GUIDED THERAPEUTCS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, GUIDED THERAPEUTCS INC (GTHP) held $63K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.1M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is GUIDED THERAPEUTCS INC's debt-to-equity ratio negative or not reported?

GUIDED THERAPEUTCS INC (GTHP) has negative shareholder equity of -$6.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is GUIDED THERAPEUTCS INC's Altman Z-Score?

GUIDED THERAPEUTCS INC (GTHP) has an Altman Z-Score of -175.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is GUIDED THERAPEUTCS INC's Piotroski F-Score?

GUIDED THERAPEUTCS INC (GTHP) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are GUIDED THERAPEUTCS INC's earnings high quality?

GUIDED THERAPEUTCS INC (GTHP) reported a net loss of $3.2M while operations used $1.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can GUIDED THERAPEUTCS INC cover its interest payments?

GUIDED THERAPEUTCS INC (GTHP) reported an operating loss of $2.4M against $617K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.